Showing 12,281 - 12,300 results of 13,825 for search '"Academy"', query time: 0.07s Refine Results
  1. 12281
  2. 12282
  3. 12283
  4. 12284
  5. 12285
  6. 12286
  7. 12287
  8. 12288
  9. 12289
  10. 12290
  11. 12291
  12. 12292
  13. 12293
  14. 12294
  15. 12295

    Dynamic Complement Protein Changes in Aqueous Humor and Plasma of Patients With Retinal Vein Occlusion During Ranibizumab Treatment by Guo T, Zhao Y, Liang S, Wang J, Liu H, Zhou Y, Xu H, Chen Z

    Published 2025-01-01
    “…Tingting Guo,1,2,* Yanying Zhao,2,3,* Shengnan Liang,2,3 Jie Wang,2 Hengwei Liu,2 Yufan Zhou,2 Heping Xu,3– 5 Zhongping Chen1– 3,6 1Aier Eye Hospital, Jinan University, Guangzhou, People’s Republic of China; 2Changsha Aier Eye Hospital, Changsha, People’s Republic of China; 3Aier Academy of Ophthalmology, Central South University, Changsha, People’s Republic of China; 4Aier Institute of Optometry and Vision Science, Aier Eye Hospital Group, Changsha, People’s Republic of China; 5The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, UK; 6School of Stomatology and Ophthalmology, Xianning Medical College, Xianning, People’s Republic of China*These authors contributed equally to this workCorrespondence: Zhongping Chen; Heping Xu, Email chenzhongping@csu.edu.cn; heping.xu@qub.ac.ukPurpose: To assess dynamic changes of complement protein in aqueous humor (AH) and plasma of retinal vein occlusion (RVO) patients during ranibizumab treatment, and to explore the differential expression of complement proteins in branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO).Patients and Methods: This prospective, consecutive case series study collected AH and plasma samples from 27 RVO patients at baseline, 1 and 2 months after ranibizumab treatment, including 19 BRVO and 8 CRVO patients. …”
    Get full text
    Article
  16. 12296
  17. 12297
  18. 12298
  19. 12299
  20. 12300